Chordia Therapeutics Inc. (JP:190A)
:190A
Want to see JP:190A full AI Analyst Report?
190A Stock Chart & Stats
¥108.00
-¥9.00(-2.81%)
At close: 4:00 PM EST
¥108.00
-¥9.00(-2.81%)
Day’s Range― - ―
52-Week Range¥98.00 - ¥241.00
Previous CloseN/A
Volume2.20M
Average Volume (3M)565.44K
Market Cap
¥8.94B
Enterprise Value¥6.20B
Total Cash (Recent Filing)¥2.55B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Jul 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-26.05
Shares Outstanding76,392,400
10 Day Avg. Volume542,310
30 Day Avg. Volume565,443
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)5.07
Price to Sales (P/S)0.00
P/FCF Ratio-6.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
No Reported Debt / Low LeverageZero reported debt reduces solvency risk and preserves strategic optionality over the next several months. For an R&D-focused biotech this lowers mandatory interest expenses and gives management flexibility to prioritize trials, partnerships or selective financing without immediate debt service pressure.
Proven 2023 Revenue And ProfitabilityHaving achieved revenue and profitability in 2023 demonstrates the business model can monetize assets or partnerships. This historical commercial traction validates technological or licensing potential and supports realistic paths to revenue recovery through collaborations or milestone-driven deals.
Focused Oncology Small-molecule R&DA clear strategic focus on oncology small-molecule discovery aligns with durable structural demand and frequent partnership interest from larger pharma. Specialization supports technical expertise, clearer go‑to‑market partnership theses, and potentially faster value-accretive collaborations versus unfocused pipelines.
Bears Say
Zero Revenue And Large Net Losses (2024–2025)Reversion to zero revenue and deep net losses materially increases execution risk and reduces internal funding capacity. Over a multi‑month horizon, absence of sales means reliance on external capital or partnerships to sustain R&D, raising dilution or operational disruption risk if financing is constrained.
Sustained Negative Operating Cash FlowPersistent negative operating cash flow reflects real cash burn from development activity and weak near-term cash generation. This erodes runway and forces management to seek financing or partnerships, which can delay programs or dilute shareholders and constrain strategic investment choices for several months.
Declining Equity And Shrinking Asset BaseMaterial equity erosion and reduced assets weaken the capital buffer available to absorb setbacks and limit balance sheet resilience. Over time this reduces negotiating leverage with partners and raises the probability management must pursue dilutive financing or asset sales to sustain development programs.
Chordia Therapeutics Inc. News
190A FAQ
What was Chordia Therapeutics Inc.’s price range in the past 12 months?
Chordia Therapeutics Inc. lowest stock price was ¥98.00 and its highest was ¥241.00 in the past 12 months.
What is Chordia Therapeutics Inc.’s market cap?
Chordia Therapeutics Inc.’s market cap is ¥8.94B.
When is Chordia Therapeutics Inc.’s upcoming earnings report date?
Chordia Therapeutics Inc.’s upcoming earnings report date is Jul 20, 2026 which is in 60 days.
How were Chordia Therapeutics Inc.’s earnings last quarter?
Chordia Therapeutics Inc. released its earnings results on Apr 10, 2026. The company reported -¥4.71 earnings per share for the quarter, missing the consensus estimate of N/A by -¥4.71.
Is Chordia Therapeutics Inc. overvalued?
According to Wall Street analysts Chordia Therapeutics Inc.’s price is currently Overvalued.
Does Chordia Therapeutics Inc. pay dividends?
Chordia Therapeutics Inc. does not currently pay dividends.
What is Chordia Therapeutics Inc.’s EPS estimate?
Chordia Therapeutics Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Chordia Therapeutics Inc. have?
Chordia Therapeutics Inc. has 76,392,400 shares outstanding.
What happened to Chordia Therapeutics Inc.’s price movement after its last earnings report?
Chordia Therapeutics Inc. reported an EPS of -¥4.71 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.775%.
Which hedge fund is a major shareholder of Chordia Therapeutics Inc.?
Currently, no hedge funds are holding shares in JP:190A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Chordia Therapeutics Inc.
Chordia is focused on the oncology area, with its target areas ranging from exploratory research to Proof of Concept (POC). For subsequent business development, we will build a system that allows us to make the best choices for maximizing corporate value, such as out-licensing and joint development and sales.
Technical Analysis
Pharmarise Holdings Corp.
―
COSMOS Pharmaceutical Corporation
―
Tsubota Laboratory Incorporated
―
Shinnihonseiyaku Co., Ltd.
―
Heartseed, Inc.
―